Transcriptome analysis of doxorubicin-treated MCF7 breat cancer cells

Doxorubicin (DOX) is the most common chemotherapeutic drug used to treat breast cancer(BC), impairing DNA metabolism. We discovered that this drug induces, in breast cancer cells, the selective degradation of mitochondria suggesting that mitophagy could be a pro-survival path induced by DOX, hence favoring drug resistance. We anticipated that BC cells may avoid the effect of drug treatment by enhancing their mitophagy activity. Our goal was here to identify a novel relationship between mitophagy gene expressions and drug resistance in BC cells. This microarray analysis of MCF7 cells was performed to demonstrate a direct modulation of genes encoding key proteins regulating the mitophagy pathway in the cells treated with DOX compared to untreated control cells. A total of n=16 samples were processed. The samples are divided into 2 experimental groups: untreated control samples (n=8) and DOX treated samples (n=8). Samples were treated for 24h with DOX 30 µM.